SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Gilead Expands Access to Investigational Ebola Drug Through Voluntary Licensing

Gilead said it is expanding access to investigational obeldesivir for Ebola Bundibugyo virus disease through voluntary licensing.

GILD

Story updates

09:05:28 PM UTC
SquawkNews
Gilead Sciences, Inc. (NASDAQ:GILD) today announced that it has signed royalty-free voluntary licensing agreements with three generic manufacturers to support potential future access to its investigational antiviral obeldesivir as post-exposure prophylaxis (PEP) for Ebola Bundibugyo virus disease…
09:05:32 PM UTC
SquawkNews
Agreements Signed in Advance of Results from the Ebola Post-Exposure Prophylaxis Field Trial and P

Related stories